Collins R L, Hodgen G D
J Clin Endocrinol Metab. 1986 Dec;63(6):1270-6. doi: 10.1210/jcem-63-6-1270.
Preovulatory ovarian secretion of progesterone (P4), several hours before the onset of the typical midcycle gonadotropin surge, occurs in humans and monkeys. We investigated the potentially obligatory role of preovulatory P4 secretion in stimulating the midcycle LH surge by administering a potent P4 antagonist, RU 486(17 beta-hydroxy-11 beta-[4-dimethylaminophenyl-1]17 alpha-[prop-1-ynyl]estra-4,9-dien-3-one), to sexually mature, normally ovulatory cynomolgus monkeys on days 10-12 of the menstrual cycle (n = 18). Monkeys were randomized to receive RU 486 alone (5 mg/day, im; group I); RU 486 plus dexamethasone (1 mg/day, im; group II); dexamethasone alone (group III); or vehicle (ethanol; 0.5 ml; group IV). Before drug treatment, the follicular phases were quite similar among groups. The administration of RU 486 blocked (delayed) the expected gonadotropin surge, despite rising estrogen concentrations (greater than 250 pg/ml). The expected LH surge was delayed by RU 486 (n = 5) or RU 486 with dexamethasone (n = 3) until 36 +/- 7 (+/- SEM) and 27 +/- 8 days in groups I and II, respectively. In contrast, groups III (n = 3) and IV (n = 5) had timely midcycle surges after the administration of dexamethasone or vehicle alone (4 +/- 2 and 6 +/- 2 days, respectively). The intermenstrual interval was lengthened by RU 486 administration in both group I and II animals (61 +/- 6 and 54 +/- 6 days) compared to controls (30 +/- 2; P less than 0.0001). In summary, RU 486 effectively blocked imminent midcycle gonadotropin surges, delayed subsequent folliculogenesis, and significantly extended the menstrual cycle length. If RU 486 acted as a pure P4 antagonist, then P4 is necessary for timely midcycle gonadotropin surges to occur. However, recent evidence showing agonistic properties of RU 486 (in the virtual absence of P4) at both endometrial and pituitary levels may favor a P4-like (agonistic) blockade of the estrogen-induced FSH/LH surges by RU 486.
在人类和猴子中,排卵前卵巢会分泌孕酮(P4),发生在典型的月经周期中期促性腺激素激增开始前数小时。我们通过给性成熟、正常排卵的食蟹猴在月经周期的第10 - 12天(n = 18)注射一种强效P4拮抗剂RU 486(17β - 羟基 - 11β - [4 - 二甲基氨基苯基 - 1] - 17α - [丙 - 1 - 炔基] - 雌甾 - 4,9 - 二烯 - 3 - 酮),来研究排卵前P4分泌在刺激月经周期中期LH激增中可能的必要作用。猴子被随机分为单独接受RU 486组(5毫克/天,肌肉注射;第一组);RU 486加地塞米松组(1毫克/天,肌肉注射;第二组);单独接受地塞米松组(第三组);或接受赋形剂组(乙醇;0.5毫升;第四组)。在药物治疗前,各组的卵泡期非常相似。尽管雌激素浓度升高(大于250皮克/毫升),但RU 486的给药阻断(延迟)了预期的促性腺激素激增。预期的LH激增在第一组(n = 5)和第二组(n = 3)中分别被RU 486或RU 486与地塞米松延迟至36±7(±标准误)天和27±8天。相比之下,第三组(n = 3)和第四组(n = 5)在单独给予地塞米松或赋形剂后有适时的月经周期中期激增(分别为4±2天和6±2天)。与对照组(30±2天)相比,第一组和第二组动物注射RU 486后月经间期延长(分别为61±6天和54±6天;P < 0.0001)。总之,RU 486有效地阻断了即将到来的月经周期中期促性腺激素激增,延迟了随后的卵泡生成,并显著延长了月经周期长度。如果RU 486作为一种纯P4拮抗剂起作用,那么P4对于适时发生月经周期中期促性腺激素激增是必要的。然而,最近的证据表明RU 486在子宫内膜和垂体水平(在几乎没有P4的情况下)具有激动特性,这可能支持RU 486对雌激素诱导的FSH/LH激增具有类似P4(激动性)的阻断作用。